Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORE: Preoperative XELOX-RT in Locally Advanced Rectal Cancer
NCT00174616Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2003
- Primary completion
- Nov 2007
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and capecitabine in rectal cancer, sponsored by Sanofi. Primary endpoint: Pathological Complete Response (ypT0N0) Rate. Started Jul 2003; status: completed.
02
Drugs
oxaliplatincapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00174616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00174616.